

CIN: L70100MP1983PLC002231

MCL/SE/2024-2025

Date: 24.02.2025

Online filing at: <u>www.listing.bseindia.com</u>

To, **The General Manager** DCS-CRD **BSE Limited** Phiroze Jeejeebhoy Towers, 'A' wing Dalal Street Fort, Mumbai – 400001(M.H.)

SUBJECT: DISCLOSUER UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR U. S. FDA INSPECTION OF WHOLLY OWNED SUBSIDIARY COMPANY.

REFERENCE: MEDI-CAPS LIMITED (BSE SCRIP CODE: 523144, ISIN: INE442D01010)

Dear Sir/Madam,

With reference to the above captioned subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the United States Food & Drug Administration (USFDA) conducted a GMP inspection of the manufacturing facility of Wholly Owned Subsidiary Company i.e., Medgel Private Limited at Pithampur, Madhya Pradesh from 17th February to 21st February 2025.

At the conclusion of the inspection on 21st February 2025, Form 483 was issued to the company. We wish to clarify that there were no observations related to data integrity, and all the observations were procedural in nature. The company will work in close collaboration with the agency to address the observations and will respond to the USFDA within stipulated timeline.

The above information will also be available on the website of the Company at www.medicaps.com.

You are requested to please take on record the above said information for your reference and further needful.

This is for your information and record.

Thanking You, Yours Faithfully,

FOR MEDI-CAPS LIMITED

ABHISHEK JAIN COMPANY SECRETARY & COMPLIANCE OFFICER M.N. A36699